Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer

被引：1
|
作者：
Yamaguchi, Teppei [1 ]
Hida, Toyoaki [1 ]
机构：
[1] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi, Japan
来源：
TRANSLATIONAL CANCER RESEARCH | 2019年 / 8卷 / 08期
关键词：
PHASE-III; MAINTENANCE BEVACIZUMAB; CHEMOTHERAPY; COMBINATION; NIVOLUMAB; DOCETAXEL; EFFICACY; THERAPY; SAFETY;
D O I：
10.21037/tcr.2019.12.57
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E11 / E14
页数：4
相关论文
共 50 条
  • [21] Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer
    Sugawara, S.
    Lee, J-S
    Kang, J-H
    Kim, H. R.
    Inui, N.
    Hida, T.
    Lee, K. H.
    Yoshida, T.
    Tanaka, H.
    Yang, C-T
    Nishio, M.
    Ohe, Y.
    Tamura, T.
    Yamamoto, N.
    Yu, C-J
    Akamatsu, H.
    Namba, Y.
    Sumiyoshi, N.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2021, 32 (09) : 1137 - 1147
  • [22] Efficacy and safety of weekly nab-paclitaxel plus carboplatin advanced non-small cell lung cancer
    Satouchi, Miyako
    Okamoto, Isamu
    Sakai, Hiroshi
    Yamamoto, Nobuyuki
    Ichinose, Yukito
    Ohmatsu, Hironobu
    Nogami, Naoyuki
    Takeda, Koji
    Mitsudomi, Tetsuya
    Kasahara, Kazuo
    Negoro, Shunichi
    LUNG CANCER, 2013, 81 (01) : 97 - 101
  • [23] Quality-adjusted Outcomes Stratified by Response in Patients With Advanced Non-Small-cell Lung Cancer Receiving First-line nab-Paclitaxel/Carboplatin or Paclitaxel/Carboplatin
    Hirsh, Vera
    Wan, Yin
    Lin, Fang-Ju
    Margunato-Debay, Sandra
    Ong, Teng Tin
    Botternan, Marc
    Langer, Corey
    CLINICAL LUNG CANCER, 2018, 19 (05) : 401 - +
  • [24] PEMETREXED AND CARBOPLATIN VERSUS DOCETAXEL AND CARBOPLATIN AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED, NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (NSCLC)
    Ganju, Vinod
    Pereira, Jose
    Kim, Joo-Hang
    Magallanes, Manuel
    Lee, Dae-Ho
    Wang, Jie
    Martinez, Luis
    Barraclough, Helen
    Van Kooten, Maximiliano
    Orlando, Mauro
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S417 - S418
  • [25] Efficacy and safety of nab-paclitaxel plus platinum in non-small cell lung cancer: a meta-analysis
    Tan, Tianying
    Li, Shuangshuang
    Hu, Wenting
    Yue, Tinghui
    Zeng, Qi
    Zeng, Xingling
    Chen, Xiaochao
    Zhao, Xiangdong
    Xiao, Tianbao
    FRONTIERS IN MEDICINE, 2023, 10
  • [26] Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Non-squamous, Non-Small Cell Lung Cancer
    Brooks, Gabriel A.
    Austin, Andrea M.
    Uno, Hajime
    Dragnev, Konstantin H.
    Tosteson, Anna N. A.
    Schrag, Deborah
    JAMA NETWORK OPEN, 2018, 1 (06)
  • [27] Analysis of continuous first-line treatment with docetaxel and carboplatin for advanced non-small cell lung cancer
    Aoki, Takuya
    Ebihara, Akinori
    Yogo, Yurika
    Suemasu, Keiichi
    Sakamaki, Fumio
    ONCOLOGY LETTERS, 2014, 7 (06) : 1771 - 1777
  • [28] Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer
    Yang, Yunpeng
    Wu, Bin
    Huang, Linian
    Shi, Meiqi
    Liu, Yunpeng
    Zhao, Yanqiu
    Wang, Lijun
    Lu, Shun
    Chen, Gongyan
    Li, Baolan
    Xie, Conghua
    Fang, Jian
    Yang, Nong
    Zhang, Yiping
    Cui, Jiuwei
    Song, Yong
    Zhang, Cuiying
    Mei, Xiaodong
    Cao, Bangwei
    Yang, Lan
    Cheng, Ying
    Ying, Kejing
    Sun, Tao
    Ren, Biyong
    Yu, Qitao
    Liao, Zijun
    Pei, Zhidong
    Wang, Mengzhao
    Zhou, Jianying
    Yu, Shiying
    Feng, Guosheng
    Wan, Huiping
    Wang, Huaqing
    Gao, Shegan
    Wang, Jinliang
    An, Guangyu
    Geng, Yi
    Ji, Yanxia
    Yuan, Ying
    Ma, Shenglin
    Jia, Zhongyao
    Hu, Mu
    Zhou, Hui
    Yu, Jie
    Sun, Xing
    Zhang, Li
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (06) : 989 - +
  • [29] Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
    West, Howard
    McCleod, Michael
    Hussein, Maen
    Morabito, Alessandro
    Rittmeyer, Achim
    Conter, Henry J.
    Kopp, Hans-Georg
    Daniel, Davey
    McCune, Steven
    Mekhail, Tarek
    Zer, Alona
    Reinmuth, Niels
    Sadiq, Ahad
    Sandler, Alan
    Lin, Wei
    Lohmann, Tania Ochi
    Archer, Venice
    Wang, Lijia
    Kowanetz, Marcin
    Cappuzzo, Federico
    LANCET ONCOLOGY, 2019, 20 (07) : 924 - 937
  • [30] Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naive metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study
    Xu, Bo
    Cheng, Huihui
    Li, Kunhong
    Lv, Yukai
    Zeng, Xianshang
    Liu, Tao
    Yu, Weiguang
    Guo, Wenbo
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (11) : 3029 - 3038
12345